|
Tuesday, September 1 |
|||
|
|
|
|
|
|
6:00 PM |
|
Conference Registration |
|
|
|
|
|
|
|
8:00 PM |
|
Welcome Reception / Dinner |
|
|
|
|
|
|
|
Wednesday, September 2 |
|||
|
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
|
|
9:00 AM |
|
Welcome and Opening Remarks |
|
|
|
|
|
|
|
Session I
|
|
Biosurfaces & Thromboinflammation Chairs: Bo Nilsson and Viviana Ferreira |
|
|
9:05 AM |
1 |
Linking TLR signals and immune cell derived complement in transplantation Peter Heeger |
|
|
9:30 AM |
2 |
Assessing the role of mannan-binding lectin in T cell reactivity and graft-versus-host disease David Heja, Sabine Heitzeneder and Alexander Dohnal |
|
|
09:45 AM |
3 |
The role of complement system in GVHD Qing Ma, Vahid Afshar-Kharghan, Dan Li, Roza Nurieva, Amin Alousi and Richard Champlin |
|
|
10:00 AM |
4 |
The crosstalk between the complement and coagulation system after trauma is mediated by leukocytes Markus Huber-Lang, Stephanie Denk and Rebecca Wiegner |
|
|
10:25 AM |
5 |
Differential roles for properdin and complement activity in the formation of platelet/granulocyte and platelet/monocyte aggregates Adam Blatt, Gurpanna Saggu, Claudio Cortes, Daniel Ricklin, John Lambris, Joshua Thurman and Viviana Ferreira |
|
|
10:40 AM |
6 |
Reciprocal relationship between complement and contact system activation on artificial polymers exposed to whole human blood Kristina Ekdahl |
|
|
11:05 AM |
7 |
Characterization and optimization of the Factor H-binding peptide 5C6 as complement-protective coating of artificial surfaces Daniel Ricklin, Sophia Koutsogiannaki, Yiannis Sarigiannis, Malvina Papanastasiou, Siddhi Ramesh, Sarah Hughes, Christoph Schmidt, Kristina Ekdahl, Bo Nilsson and John Lambris |
|
|
|
|
|
|
|
11:30 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
|
|
Session II: |
|
Targets & Inhibitors: Amplification & Effector Pathways Chairs: Michael Holers and Mihály Józsi |
|
|
12:00 PM |
8 |
An update on the preclinical and clinical development of the therapeutic C3 inhibitor Cp40 John Lambris, Edimara Reis, Malvina Papanastasiou, Alexandra Primikyri, Sophia Koutsogiannaki, Hongbin Wang, Yiannis Sarigiannis, Sotirios Koutsopoulos, Gang Chen, Markus Huber-Lang, Bo Nilsson, Kristina Ekdahl, Alireza Biglarnia, Richard Smith, George Hajishengallis, Antonio Risitano, Despina Yancopoulou and Daniel Ricklin |
|
|
12:25 PM |
9 |
Discovery of highly potent and selective orally bioavailable alternative pathway complement inhibitors? Stefanie Flohr |
|
|
12:40 PM |
10 |
C3-opsonin targeted complement inhibitors: advantageous molecular features for host-cell selectivity and efficient control of the alternative pathway Christoph Schmidt, Markus Harder, Thomas Simmet, Markus Huber-Lang, Daniel Ricklin and John Lambris |
|
|
12:55 PM |
11 |
Characterization of anti-properdin monoclonal antibodies in their ability to recognize physiological forms of human properdin and inhibit their function Adam Blatt, Heather Emch, Koustubh Kulkarni, Sabina Pathan, Megan Bickford, Saad Moledina, Cara DeAngelis, Claudio Cortes, Joshua Thurman and Viviana Ferreira |
|
|
1:10 PM |
12 |
Structures of multiply inhibited complement C5 reveal mechanisms underlying therapeutic inhibition Susan Lea |
|
|
1:35 PM |
13 |
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement Mediated Diseases: Initial Phase 1 Study Results in Healthy Volunteers Benny Sorensen, Jorg Taubel, Jim Bush, Anna Borodovsky, Noriyuki Kawahata, Lauren Melton, Jennifer Panagoulias, Jeffery Cehelsky, Helen Mclean, Christine Powell, Kristina Yucius, Renta Hutabarat, Prasoon Chaturvedi, Garvin Warner, David Salant, V. Michael Holers, Nirmal Banda, Linda Kusner, Henry Kaminski, Akshay Vaishnaw and Pushkal Garg |
|
|
1:50 PM |
14 |
Dissecting the terminal complement pathway with a macrocyclic peptide inhibitor of assembly of the membrane attack complex Kathleen Seyb, M Arata, D Vadysirisack, GQ Tang, K Dhamnaskar, C Blain, K Josephson, A Ricardo and D Treco |
|
|
2:05 PM |
15 |
The complement system in metabolic disease Julia Phieler, Antonios Chatzigeorgiou, Kyoung-Jin Chung, John Lambris and Triantafyllos Chavakis |
|
|
2:30 PM |
|
Lunch and Informal Discussions |
|
|
|
|
|
|
|
7:30 PM |
|
Dinner and Informal Discussion |
|
|
|
|
|
|
|
Thursday, September 3 |
|||
|
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
|
|
Session III |
|
Eye, Kidney & Urinary Tract Disorders Chairs: Gregory Stahl and Joshua Thurman |
|
|
9:00 AM |
16 |
Complement activation by C3 and C5 convertases contributes to photoreceptor degeneration Kenneth Katschke, Hongkang Xi, Tom Truong, Wyne Pun Lee, Lauri Diehl, Jianhua Tao, Mike Reichelt and Menno van Lookeren Campagne |
|
|
9:25 AM |
17 |
Collectin-11 as a trigger of the innate immune response in renal inflammation Steven Sacks, W. Zhou, W. Schwaeble, C. Farrar and D. Tran |
|
|
9:50 AM |
18 |
Mice carrying a homozygous W1183R mutation in SCR20 of factor H develop highly penetrant and severe atypical hemolytic uremic syndrome Yoshiyasu Ueda, Takashi Miwa, Lin Zhou, Imran Mohammed, Damodar Gullipalli, Sayaka Sato and Wenchao Song |
|
|
10:15 AM |
19 |
Factor H-related proteins in the activation and regulation of complement Mihály Józsi |
|
|
10:40 AM |
20 |
Inhibition of the C5a Receptor by CCX168 Markedly Reduces the Thrombogenic Potential of Serum from Patients with atypical Hemolytic Uremic Syndrome Shijie Li |
|
|
10:55 AM |
21 |
The role of anaphylatoxin receptors in urinary tract infection Wuding Zhou |
|
|
|
|
|
|
|
11:20 AM |
|
Coffee Break & Poster Viewing |
|
|
|
|
|
|
|
Session IV |
|
Targets & Inhibitors: Initiation Pathways Chairs: Andrea Tenner and Sacha Zeerleder |
|
|
11:50 AM |
22 |
The lectin pathway as a therapeutic target for upstream complement inhibition Peter Garred |
|
|
12:15 PM |
23 |
Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury Masayuki Ozaki, Yulin Kang, Vasile Pavlov, Bohan Liu, Rafail Kushak, Mikkel-Ole Skjoedt, Eric Grabowski, Yasuhiko Taira and Gregory Stahl |
|
|
12:40 PM |
24 |
As a key player in the assembly of the kinin/kallikrein system that leads to the generation of bradykinin, gC1qR is a suitable therapeutic target for the treatment of angioedema Berhane Ghebrehiwet and Ellinor Peerschke |
|
|
1:05 PM |
25 |
TNT009 – First-in-Class Anti-C1s Antibody: Phase 1a/1b Trial for Classical Complement-Mediated Diseases Adam Rosenthal, Nancy Stagliano, Graham Parry, Sandip Panicker and Jim Gilbert |
|
|
1:20 PM |
26 |
Peptide Inhibitor of Complement C1 (PIC1) Enhances Survival of Human Erythrocytes in an Animal Model of Acute Intravascular Hemolytic Transfusion Reaction Neel Krishna, Kenji Cunnion, Parvathi Kumar, Tushar Shah, Alice Werner, Frank Lattanzio, Haree Pallera and Pamela Hair |
|
|
1:35 PM |
27 |
Pathogenic Natural Antibodies: Common Neoepitopes Found Across Multiple Disease Models and Use as Targeting Modules for Novel Complement Inhibitors Stephen Tomlinson, Liudmila Kulik, Carl Atkinson, Nirmal Banda, Barbel Rohrer, Joshua Thurman and Michael Holers |
|
|
2:00 PM |
28 |
Is C3 a contact-activated protein? Bo Nilsson |
|
|
|
|
|
|
|
2:25 PM |
|
Lunch and Informal Discussions |
|
|
|
|
|
|
|
7:30 PM |
|
Dinner and Informal Discussion |
|
|
|
|
|
|
|
Friday, September 4 |
|||
|
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
|
|
Session V |
|
Cancer Biology & Therapy Chairs: Berhane Ghebrehiwet and Trent Woodruff |
|
|
9:00 AM |
29 |
Interaction of PTX3 with complement in the regulation of inflammation and cancer Alberto Mantovani |
|
|
9:25 AM |
30 |
The Molecular Sequence of Events Leading to Complement-dependent-cytotoxicity of Cell lines and of Chronic Lymphocytic Leukemia cells is Accelerated for CD20 Antibodies Harboring Mutations that Enhance Hexamer Formation Ronald Taylor, Margaret Lindorfer, Erika Cook, Clive Zent, Richard Burack, Frank Beurskens, Janine Schuurman and Paul Parren |
|
|
9:50 AM |
31 |
Soluble gC1qR in Blood and Body Fluids: Examination in a pancreatic cancer patient cohort Ellinor Peerschke, Ricardo Brandwijk, Francine Dembitzer, Yayoi Kinoshita and Berhane Ghebrehiwet |
|
|
10:15 AM |
32 |
Opposing Roles for Complement C5a Receptors, C5aR1 and C5aR2, in a Murine Model of Melanoma Jamileh Nabizadeh, Helga Manthey, Derik Steyn, Fazrena Akhir, Weiyu Chen, Glen Boyle, Stephen Taylor, Trent Woodruff and Barbara Rolfe |
|
|
10:30 AM |
33 |
C3-deficiency is associated with reduced tumor growth in carcinogen-induced epithelial and mesenchymal murine cancer models Elena Magrini, Eduardo Bonavita, Stefania Gentile, Alberto Mantovani and Cecilia Garlanda |
|
|
10:45 AM |
34 |
The dual role of C3a-C3aR axis during intestinal inflammation and tumorigenesis Silvia Guglietta, Elena Zagato, Carsten Krieg, Sara Gandini, Paola Ravenda, Bao Lu, Giuseppe Penna and Maria Rescigno |
|
|
|
|
|
|
|
11:00 AM |
|
Coffee Break & Poster Viewing |
|
|
|
|
|
|
|
Session VI |
|
Infectious Diseases & Mucosal Inflammation Chairs: Anna Blom and Jörg Köhl |
|
|
11:40 AM |
35 |
Molecular interplay between complement and bacteria. Suzan Rooijakkers |
|
|
12:05 PM |
36 |
Harnessing the sialylation machinery of Neisseria gonorrhoeae to design novel immunotherapeutics against multidrug-resistant gonorrhea Sunita Gulati, Ian Schoenhofen, Dennis Whitfield, Andrew Cox, Bo Zheng, Makoto Ohnishi, Magnus Unemo, Lisa Lewis, Rachel Taylor, Corinna Landig, Sandra Diaz, George Reed, Ajit Varki, Peter Rice and Sanjay Ram |
|
|
12:30 PM |
37 |
Towards novel antimicrobial therapeutics: Efb-targeting mini-antibodies attenuate S. aureus survival in models of bacterial inflammation Maria Georgoutsou-Spyridonos, Daniel Ricklin, Haris Pratsinis, Eustathia Perivolioti, Ioannis Pirmettis, Brandon Garcia, Brian Geisbrecht, Periklis Foukas, John Lambris, Dimitrios Mastellos and Georgia Sfyroera |
|
|
12:45 PM |
38 |
Inhibition of pre-existing natural periodontal inflammation in non-human primates by a locally administered peptide inhibitor of complement C3 George Hajishengallis, Tomoki Maekawa, Ruel Briones, Joel Tuplano, Ranillo Resuello, Sophia Koutsogiannaki, Cristina Garcia, Evlambia Hajishengallis, Daniel Ricklin and John Lambris |
|
|
1:10 PM |
39 |
Treponema denticola, complement dysregulation and periodontal disease Richard Marconi, Daniel Miller and Lee Oliver |
|
|
1:35 PM |
40 |
Noninvasive Detection of Tuberculosis-Associated Inflammation with a Radioiodinated Anti-C3d Monoclonal Antibody Catherine Foss, Liudmila Kulik, Alvaro Ordonez, Sanjay Jain, Martin Pomper, Michael Holers and Joshua Thurman |
|
|
|
|
|
|
|
2:00 PM |
|
Lunch and Informal Discussions |
|
|
|
|
|
|
|
3:30 PM |
|
City Tour |
|
|
|
|
|
|
|
7:30 PM |
|
Dinner and Informal Discussion |
|
|
|
|
|
|
|
Saturday, September 5 |
|||
|
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
|
|
Session VII |
|
Neurological & Hematological Disorders Chairs: Wenchao Song and Christoph Schmidt |
|
|
9:00 AM |
41 |
Strategic Targeting of the Complement System to Control Neurodegeneration in Alzheimer’s Disease Andrea J. Tenner and Michael X. Hernandez |
|
|
9:25 AM |
42 |
Complement peptides C3a and C5a exert opposing roles in a mouse model of amyotrophic lateral sclerosis: Therapeutic considerations for targeting complement in neurodegenerative disease. John Lee, Peter Noakes and Trent Woodruff |
|
|
9:50 AM |
43 |
The Complement Receptor C5aR1 Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury Faith Brennan, Richard Gordon, Hong Lao, Patrick Biggins, Stephen Taylor, Robin Franklin, Trent Woodruff and Marc Ruitenberg |
|
|
10:05 AM |
44 |
Complement Components and Complement Inhibitory Proteins in Regulating Neuro-Inflammation Chantal Moratz, Huazhen Chen, Joseph McCabe and Matthew Myers |
|
|
10:20 AM |
45 |
Complement activation in Autoimmune Hemolytic Anemia solely mediated by classical pathway Sacha Zeerleder, Elisabeth Meulenbroek, Gerard van Mierlo, Conny Brouwer, Claudia Folman, Masja de Haas and Diana Wouters |
|
|
10:45 AM |
46 |
What a PNH physician ask for to a second generation complement inhibitor Antonio Risitano |
|
|
11:10 AM |
47 |
Funding Translational Research and Development of Life Sciences Innovation – Sources and Strategies to Create Novel Therapeutics and Diagnostics Charles Baltic |
|
|
|
|
|
|
|
11:35 AM |
|
Coffee Break and Poster Viewing |
|
|
|
|
|
|
|
Session VIII |
Acute & chronic Inflammation Chairs: Markus Huber-Lang and Antonio Risitano |
||
|
12:00 PM |
48 |
Factor H uptake regulates intracellular C3 activation during apoptosis and decreases the inflammatory potential of nucleosomes Myriam Martin, Jonatan Leffler, Karolina Smolag, Jennifer Mytych, Albin Björk, Lee Chaves, Jessy Alexander, Richard Quigg and Anna Blom |
|
|
12:25 PM |
49 |
C5a drives the inflammatory response in food allergy Anna Czabanska, Simon Hogan and Jörg Köhl |
|
|
12:50 PM |
50 |
Complement-mediated pseudoallergic reactions to intravenous drugs: Recent progress in modelling in animals, prediction and prevention Janos Szebeni |
|
|
1:05 PM |
51 |
A novel treatment regimen for inflammatory diseases: targeting the interaction between the complement system and CD14 Tom Mollnes and Terje Espevik |
|
|
1:30 PM |
52 |
Direct cell activation by a complement protease: a novel mechanism for initiation of inflammation Peter Gal |
|
|
1:55 PM |
53 |
C5aR1 activation in LysM-expressing cells regulates pulmonary CD4+ T cell and innate immune cell type 2 accumulation in experimental allergic asthma Yves Laumonnier, Anna Wiese, Fanny Ender, Inken Schmudde, Tillman Vollbrandt, Peter König and Jörg Köhl |
|
|
2:10 PM |
54 |
Complement triggers both Signals 1 and 2 for inflammasome activation in the atherosclerotic plaque Martha Triantafilou, Timothy Hughes, Ruth Lewis, Paul Morgan and Kathy Triantafilou |
|
|
|
|
|
|
|
2:25 PM |
|
Closing Remarks |
|
|
|
|
|
|
|
2:30 PM |
|
Lunch and Informal Discussions |
|
|
|
|
|
|
|
7:30 PM |
|
Farewell Dinner |
|
|
|
|
|
|
|
Sunday, September 6 |
|||
|
|
|
|
|
|
7:30 AM |
|
Breakfast |
|
|
|
|
|
|
|
|
|
Departure |
|
|
Posters |
|||
|
|
|
|
|
|
55 |
Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo Elena Volokhina, Grethe Bergseth, Nicole van de Kar, Lambertus van den Heuvel and Tom Eirik Mollnes |
||
|
56 |
Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in a Atypical Hemolytic Uremic Syndrome. Elena Volokhina, Nicole van de Kar, Grethe Bergseth , Thea van der Velden, Dineke Westra, Jack Wetzels, Lambertus van den Heuvel and Tom Eirik Mollnes |
||
|
57 |
Complement activation in Auto-Immune Hemolytic Anemia as footprint for difficult-to-detect IgM-autoantibodies Sacha Zeerleder, Elisabeth Meulenbroek, Conny Brouwer, Claudia Folman, Masja de haas and Diana Wouter |
||
|
58 |
The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses Barbara Rolfe, Jamileh Nabizadeh, Helga Manthey, Glen Boyle, Frederik Steyn, Stephen Taylor and Trent Woodruff |
||
|
59 |
Pre-operative ficolin-3 concentrations in relation to complications following pediatric cardiac surgery. Mateusz Michalski, Anna Świerzko, Maciej Cedzyński, Wojciech Krajewski, Maciej Moll and Izabela Pągowska-Klimek |
||
|
60 |
Complement lectin pathway activation by cardiopulmonary bypass contributes to the development of systemic inflammatory response syndrome after pediatric cardiac surgery. Izabela Pagowska-Klimek, Anna Swierzko, Mateusz Michalski, Maciej Moll, Agnieszka Szala-Pozdziej, Anna Sokolowska, Wojciech Krajewski and Maciej Cedzynski |
||
|
61 |
Mannose-binding lectin (MBL) and postoperative complications rate in pediatric cardiac surgery. Izabela Pągowska-Klimek, Anna Świerzko, Mateusz Michalski, Maciej Moll, Agnieszka Szala, Anna Sokołowska, Wojciech Krajewski and Maciej Cedzyński |
||
|
62 |
Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration. Vinod Kumar, John Lee, Peter Noakes and Trent Woodruff |
||
|
63 |
Discovery of small molecules for fluorescent detection of complement activation product C3d Ronald Gorham Jr., Vicente Nuñez, Jung-Hsin Lin, Suzan Rooijakkers, Valentine Vullev and Dimitrios Morikis |
||
|
64 |
TNT003, a monoclonal antibody targeting complement component C1s, effectively blocks alloantibody-induced classical complement pathway activation in vitro Markus Wahrmann, Jakob Mühlbacher, Lena Marinova, Nicole Huttary, Heinz Regele, Farsad Eskandary, James Gilbert, Sandip Panicker and Georg Böhmig |
||
|
65 |
MARCH more than complimentary: Novel substrate partners of MARCH-1 in plasma membrane regulation on B cells and DCs Alan Ching, Pauline Huang, Giuseppe Infusini, Justine Mintern and Jose Villadangos |
||
|
66 |
Selected factors of complement lectin pathway in Polish children with juvenile idiopathic arthritis Katarzyna Kasperkiewicz, Mateusz Michalski, Lukasz Eppa, Marcin Bartlomiejczyk, Anna Swierzko, Zbigniew Zuber, Elzbieta Mezyk, Magdalena Noszczynska and Maciej Cedzynski |
||
|
67 |
Expression Profiles of the Complement Components in Chronic Rhinosinusitis with Nasal Polyps Ulrike Werner, Michael Könnecke, Ralph Pries and Barbara Wollenberg |
||
|
68 |
Function relationships of Fc gamma receptor II and CR3 in etiopathogenesis of sarcoidosis Anna Dubaniewicz, Monika Skotarczak, Piotr Trzonkowski and Marlena Typiak |
||
|
69 |
PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer Eduardo Bonavita, Stefania Gentile, Marcello Rubino, Virginia Maina, Roberto Papait, Martina Molgora, Andrea Doni, John Lambris, Sebastien Jaillon, Cecilia Garlanda and Alberto Mantovani |
||